| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
Departments of 1 Gynecology and Obstetrics and Oncology, and 2 Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland; and 3 Department of Pathology, Norwegian Radium Hospital, University of Oslo, Oslo, Norway
Requests for reprints: Tian-Li Wang, Departments of Gynecology/Obstetrics and Oncology, Johns Hopkins University School of Medicine, CRBII, 1550 East Jefferson Street, Room 306, Baltimore, MD 21231. Phone: 410-502-7774; Fax: 410-502-7943; E-mail: tlw{at}jhmi.edu.
Gene amplification is one of the common mechanisms that activate oncogenes. In this study, we used single nucleotide polymorphism array to analyze genome-wide DNA copy number alterations in 31 high-grade ovarian serous carcinomas, the most lethal gynecologic neoplastic disease in women. We identified an amplicon at 19p13.12 in 6 of 31 (19.5%) ovarian high-grade serous carcinomas. This amplification was validated by digital karyotyping, quantitative real-time PCR, and dual-color fluorescence in situ hybridization (FISH) analysis. Comprehensive mRNA expression analysis of all 34 genes within the minimal amplicon identified Notch3 as the gene that showed most significant overexpression in amplified tumors compared with nonamplified tumors. Furthermore, Notch3 DNA copy number is positively correlated with Notch3 protein expression based on parallel immunohistochemistry and FISH studies in 111 high-grade tumors. Inactivation of Notch3 by both
-secretase inhibitor and Notch3-specific small interfering RNA suppressed cell proliferation and induced apoptosis in the cell lines that overexpressed Notch3 but not in those with minimal amount of Notch3 expression. These results indicate that Notch3 is required for proliferation and survival of Notch3-amplified tumors and inactivation of Notch3 can be a potential therapeutic approach for ovarian carcinomas. (Cancer Res 2006; 66(12): 6312-8)
This article has been cited by other articles:
![]() |
K.-T. Kuo, B. Guan, Y. Feng, T.-L. Mao, X. Chen, N. Jinawath, Y. Wang, R. J. Kurman, I.-M. Shih, and T.-L. Wang Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas Cancer Res., May 1, 2009; 69(9): 4036 - 4042. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Meng, X. Zhang, K. D. Hankenson, and M. M. Wang Thrombospondin 2 Potentiates Notch3/Jagged1 Signaling J. Biol. Chem., March 20, 2009; 284(12): 7866 - 7874. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Indraccolo, S. Minuzzo, M. Masiero, I. Pusceddu, L. Persano, L. Moserle, A. Reboldi, E. Favaro, M. Mecarozzi, G. Di Mario, et al. Cross-talk between Tumor and Endothelial Cells Involving the Notch3-Dll4 Interaction Marks Escape from Tumor Dormancy Cancer Res., February 15, 2009; 69(4): 1314 - 1323. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Etemadmoghadam, A. deFazio, R. Beroukhim, C. Mermel, J. George, G. Getz, R. Tothill, A. Okamoto, M. B. Raeder, AOCS Study Group, et al. Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas Clin. Cancer Res., February 15, 2009; 15(4): 1417 - 1427. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Park, I.-M. Shih, and T.-L. Wang Identification of Pbx1, a Potential Oncogene, as a Notch3 Target Gene in Ovarian Cancer Cancer Res., November 1, 2008; 68(21): 8852 - 8860. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shehata, I. Bieche, R. Boutros, J. Weidenhofer, S. Fanayan, L. Spalding, N. Zeps, K. Byth, R. K. Bright, R. Lidereau, et al. Nonredundant Functions for Tumor Protein D52-Like Proteins Support Specific Targeting of TPD52 Clin. Cancer Res., August 15, 2008; 14(16): 5050 - 5060. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Choi, J. T. Park, B. Davidson, P. J. Morin, I.-M. Shih, and T.-L. Wang Jagged-1 and Notch3 Juxtacrine Loop Regulates Ovarian Tumor Growth and Adhesion Cancer Res., July 15, 2008; 68(14): 5716 - 5723. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Wu, Y.-T. Lin, R. Wei, Y. Chen, Z. Shan, and W.-H. Lee Hice1, a Novel Microtubule-Associated Protein Required for Maintenance of Spindle Integrity and Chromosomal Stability in Human Cells Mol. Cell. Biol., June 1, 2008; 28(11): 3652 - 3662. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sugimura Detection of chromosome changes in pathology archives: an application of microwave-assisted fluorescence in situ hybridization to human carcinogenesis studies Carcinogenesis, April 1, 2008; 29(4): 681 - 687. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Li, Y. Li, W. Wu, W. R. Gordon, D. W. Chang, M. Lu, S. Scoggin, T. Fu, L. Vien, G. Histen, et al. Modulation of Notch Signaling by Antibodies Specific for the Extracellular Negative Regulatory Region of NOTCH3 J. Biol. Chem., March 21, 2008; 283(12): 8046 - 8054. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Yamaguchi, T. Oyama, E. Ito, H. Satoh, S. Azuma, M. Hayashi, K. Shimizu, R. Honma, Y. Yanagisawa, A. Nishikawa, et al. NOTCH3 Signaling Pathway Plays Crucial Roles in the Proliferation of ErbB2-Negative Human Breast Cancer Cells Cancer Res., March 15, 2008; 68(6): 1881 - 1888. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kennard, H. Liu, and B. Lilly Transforming Growth Factor- (TGF- 1) Down-regulates Notch3 in Fibroblasts to Promote Smooth Muscle Gene Expression J. Biol. Chem., January 18, 2008; 283(3): 1324 - 1333. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. O'Neill, S. Urs, C. Cinelli, A. Lincoln, R. J. Nadeau, R. Leon, J. Toher, C. Mouta-Bellum, R. E. Friesel, and L. Liaw Notch2 Signaling Induces Apoptosis and Inhibits Human MDA-MB-231 Xenograft Growth Am. J. Pathol., September 1, 2007; 171(3): 1023 - 1036. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. O'Neil, J. Grim, P. Strack, S. Rao, D. Tibbitts, C. Winter, J. Hardwick, M. Welcker, J. P. Meijerink, R. Pieters, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to {gamma}-secretase inhibitors J. Exp. Med., August 6, 2007; 204(8): 1813 - 1824. [Abstract] [Full Text] [PDF] |
||||
![]() |
I.-M. Shih and T.-L. Wang Notch Signaling, {gamma}-Secretase Inhibitors, and Cancer Therapy Cancer Res., March 1, 2007; 67(5): 1879 - 1882. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Davidson, Z. Zhang, L. Kleinberg, M. Li, V. A. Florenes, T.-L. Wang, and I.-M. Shih Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin. Cancer Res., October 15, 2006; 12(20): 5944 - 5950. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |